title: Lipopolysaccharide binding protein as a marker of inflammation in synovial fluid of patients with arthritis: correlation with interleukin 6 and C-reactive protein.
abstract: OBJECTIVE
  To determine levels of lipopolysaccharide binding protein (LBP) in serum and in synovial fluid (SF) of patients presenting with various articular disorders [degenerative arthritis, rheumatoid arthritis (RA), reactive arthritis (ReA)] and to correlate these levels with C-reactive protein (CRP) and interleukin 6 (IL-6), 2 markers of the acute phase response.
  
  
  METHODS
  LBP was measured by a radioimmunoassay made up of lipopolysaccharide (LPS) to capture LBP and radiolabelled anti-LBP antibodies to detect LBP. LBP was also measured for its ability to present fluorescein isothiocyanate LPS (FITC-LPS) to human monocytes. CRP was measured by nephelometry and IL-6 bioassay.
  
  
  RESULTS
  Levels of LBP in serum and in SF were significantly higher in patients with RA and ReA than in the control group of degenerative arthropathies. In the latter group, LBP values were similar to those found in controls. Serum LBP values correlated positively with SF LBP values. LBP values also correlated with CRP and IL-6 levels measured in SF. Functionally, LBP was found to be active and able to present LPS to monocytes, resulting in tumor necrosis factor-alpha (TNF-alpha) release upon LPS challenge.
  
  
  CONCLUSIONS
  These in vitro data support the observation that LBP could play a major role in local joint disorders. Our results also strengthen the view that LBP may be a new marker of synovial inflammation.
authors.affiliation: Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
authors.forename: D
authors.initials: D
authors.lastname: Heumann
authors.forename: S
authors.initials: S
authors.lastname: Bas
authors.forename: P
authors.initials: P
authors.lastname: Gallay
authors.forename: D
authors.initials: D
authors.lastname: Le Roy
authors.forename: C
authors.initials: C
authors.lastname: Barras
authors.forename: N
authors.initials: N
authors.lastname: Mensi
authors.forename: M P
authors.initials: MP
authors.lastname: Glauser
authors.forename: T
authors.initials: T
authors.lastname: Vischer
mesh_terms: D000209:Acute-Phase Proteins / Q000378:metabolism*; D001168:Arthritis / Q000378:metabolism*; D015415:Biomarkers / Q000032:analysis; D002097:C-Reactive Protein / Q000378:metabolism*; D002352:Carrier Proteins / Q000378:metabolism*; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D008562:Membrane Glycoproteins; D009000:Monocytes / Q000378:metabolism; D000091402:Prohibitins; D013582:Synovial Fluid / Q000737:chemistry; D013585:Synovitis / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000099231:Lipopolysaccharide-Binding Protein
chemical_list: D000209:Acute-Phase Proteins; D015415:Biomarkers; D002097:C-Reactive Protein; D002352:Carrier Proteins; D015850:Interleukin-6; D008562:Membrane Glycoproteins; D000091402:Prohibitins; D014409:Tumor Necrosis Factor-alpha; D000099231:Lipopolysaccharide-Binding Protein; C000717331:PHB2 protein, human